Article | Open

Multiple sodium channel isoforms mediate the pathological effects of Pacific ciguatoxin-1

  • Scientific Reports 7, Article number: 42810 (2017)
  • doi:10.1038/srep42810
  • Download Citation
Received:
Accepted:
Published online:

Abstract

Human intoxication with the seafood poison ciguatoxin, a dinoflagellate polyether that activates voltage-gated sodium channels (NaV), causes ciguatera, a disease characterised by gastrointestinal and neurological disturbances. We assessed the activity of the most potent congener, Pacific ciguatoxin-1 (P-CTX-1), on NaV1.1–1.9 using imaging and electrophysiological approaches. Although P-CTX-1 is essentially a non-selective NaV toxin and shifted the voltage-dependence of activation to more hyperpolarising potentials at all NaV subtypes, an increase in the inactivation time constant was observed only at NaV1.8, while the slope factor of the conductance-voltage curves was significantly increased for NaV1.7 and peak current was significantly increased for NaV1.6. Accordingly, P-CTX-1-induced visceral and cutaneous pain behaviours were significantly decreased after pharmacological inhibition of NaV1.8 and the tetrodotoxin-sensitive isoforms NaV1.7 and NaV1.6, respectively. The contribution of these isoforms to excitability of peripheral C- and A-fibre sensory neurons, confirmed using murine skin and visceral single-fibre recordings, reflects the expression pattern of NaV isoforms in peripheral sensory neurons and their contribution to membrane depolarisation, action potential initiation and propagation.

Introduction

Ciguatera is the most common non-bacterial form of fish-borne illness and is caused by the consumption of fish contaminated with ciguatoxins1. These polycyclic ethers are lipophilic, heat stable ichthyotoxins that originate from benthic dinoflagellates of the genus Gambierdiscus that bloom in tropical and sub-tropical oceans around the world. Consumption of coral and seaweed contaminated with Gambierdiscus by herbivorous fish leads to bioaccumulation of the ciguatoxins through the food chain via larger carnivorous fish that in turn are consumed by humans and cause ciguatera. The communities most affected by ciguatera are those that rely on fish as a major part of their diet such as the island nations of the Pacific and Indian Oceans and the Caribbean Sea2,3,4. However, as the world’s oceans warm and algal blooms become more frequent, ciguatera is now emerging as a significant issue in Asia, America and parts of Europe5,6,7,8.

The presenting symptoms of ciguatera are predominantly neurotoxic in the majority of cases and include post-ingestion paraesthesiae, dysaesthesiae and heightened nociception, including the pathognomonic symptom of cold allodynia, which is associated with intense discomfort on exposure to cool temperatures1,9,10,11. In addition, early signs of ciguatera include gastrointestinal symptoms such as diarrhoea, vomiting and abdominal pain as well as musculoskeletal symptoms, in particular weakness and fatigue1. Cardiovascular symptoms such as bradycardia occur more rarely and often in more severe cases of poisoning12,13,14,15. This diverse symptomatology is believed to be caused by the interaction of the ciguatoxins with site 5 of the voltage-gated sodium channels (NaV)11,16,17,18. Mammalian NaV channels NaV1.1–1.9 comprise a voltage-sensitive pore-forming α-subunit, which may also be associated with one of four auxiliary β-subunits that can modify the gating and kinetic profile of the α-subunit. The α-subunit consists of four homologous domains each containing six transmembrane segments that form the pore and facilitate voltage-sensing and ligand binding. Pacific ciguatoxin-1 (P-CTX-1), the most potent ciguatoxin congener thought to be responsible for the majority of symptoms associated with ciguatera in the Pacific19, elicits varied effects on the electrophysiological properties of NaV channels and as a consequence enhances neuronal excitability. In dorsal root ganglion (DRG) neurons, P-CTX-1 shifts the voltage of activation of tetrodotoxin-sensitive (TTX-s) NaV channels to more hyperpolarised potentials and decreases peak tetrodotoxin-resistant (TTX-r) Na+ current20. Similarly, in parasympathetic neurons P-CTX-1 enhances the open probability of single TTX-sensitive NaV channels without altering the unitary conductance or reversal potential21. However, while it is known that the ciguatoxins modulate activity of TTX-s and TTX-r NaV isoforms, the relative selectivity for and pharmacological effects on individual NaV isoforms, and their association with diverse pathophysiological consequences have not been assessed to-date. Thus, the aims of the present study were to determine the relative activity and subtype-selectivity of the most potent congener of the ciguatoxins, P-CTX-1, on the mammalian NaV isoforms NaV1.1–1.9 and to define the NaV isoforms that contribute to the in vivo symptomatology associated with ciguatera.

Results

Subtype-selectivity of P-CTX-1 at NaV1.1–1.9

Although ciguatoxin is known to affect TTX-sensitive and TTX-resistant NaV channels20, the specific effects of P-CTX-1 on individual NaV subtypes have not previously been reported. We first assessed the relative potency and selectivity of P-CTX-1 for NaV isoforms using a high-throughput membrane potential assay22. In HEK293 cells stably expressing hNaV1.1–1.8, P-CTX-1 elicited a concentration-dependent potentiation of NaV-mediated responses with little subtype-selectivity (Fig. 1a; EC50 ± SEM: NaV1.1, 7.9 ± 3.1 nM; NaV1.2, 8.3 ± 3.9 nM; NaV1.3, 3.4 ± 1.6 nM; NaV1.4, 18.4 ± 6.9 nM; NaV1.5, 10.8 ± 3.8 nM; NaV1.6, 18.1 ± 9.4 nM; NaV1.7, 13.0 ± 5.8 nM; NaV1.8, 2.1 ± 0.7 nM). Overall, NaV1.3 and NaV1.8 were most potently affected, while NaV1.4 was the isoform least potently affected, although the relative selectivity for these isoforms was not statistically significant (ANOVA, p > 0.05). These results indicate that P-CTX-1 is a potent but relatively non-specific modulator of NaV channels. Therefore, we sought to assess the effects of P-CTX-1 on the electrophysiological properties of hNaV1.1–1.9 in more detail.

Figure 1: P-CTX-1 subtype selectivity assessed using a high-throughput membrane potential FLIPRTetra assay.
Figure 1

(a) P-CTX-1 concentration-dependently potentiated veratridine-induced responses in mammalian cells heterologously expressing NaV1.1–NaV1.8 with little subtype selectivity. (b) P-CTX-1 (10 nM) induced shifts in the voltage of activation at NaV1.1–NaV1.8 and the voltage-dependence of inactivation at NaV1.2, NaV1.3 and NaV1.4. Data are presented as mean ± SEM from n = 3–6 independent experiments.

Differential effects of P-CTX-1 on the electrophysiological parameters of NaV1.1–1.9

Using whole cell patch-clamp recordings, we further assessed the effects of P-CTX-1 on the electrophysiological parameters of hNav1.1–1.9 expressed heterologously in HEK293 cells (Figs 1b and 2 and Table 1). The effect of P-CTX-1 on peak current was voltage-dependent, causing an increase in peak current at more hyperpolarised potentials at all subtypes (Fig. 2), with maximal peak current significantly increased only for NaV1.6 (Table 1). Accompanying the voltage-dependent changes in peak current, P-CTX-1 significantly shifted the V1/2 for the voltage-dependence of activation to more hyperpolarising potentials at all NaV subtypes (ΔV1/2 activation: NaV1.1, −5.1 mV; NaV1.2, −6.3 mV; NaV1.3, −5.0 mV; NaV1.4, −3.4 mV; NaV1.5, −6.1 mV; NaV1.6, −3.4 mV; NaV1.7, −5.7 mV; NaV1.8, −11.3 mV; NaV1.9, −8.9 mV; Figs 1b and 2 and Table 1). These effects are consistent with NaV channel activator activity and were not observed in time-matched controls. Interestingly, P-CTX-1 also significantly changed the slope factor of the conductance-voltage curves for NaV1.3, NaV1.6, NaV1.7 and NaV1.8 (Fig. 2 and Table 1). For NaV1.3, NaV1.6 and NaV1.8, the slope factor decreased, indicating higher conductance at more depolarised membrane potentials, whilst for NaV1.7 the slope factor increased, indicating higher conductance at more hyperpolarised membrane potentials.

Figure 2: Effects of P-CTX-1 on the electrophysiological parameters of NaV1.1–1.9 assessed by automated whole-cell patch clamping in mammalian cells.
Figure 2

P-CTX-1 (white triangles) caused a leftward shift in the I-V curves at all NaV subtypes compared to control (black triangles). P-CTX-1 (white circles) significantly shifted the V1/2 of voltage-dependence of activation to more hyperpolarised potentials at all NaV subtypes compared to control (black circles). P-CTX-1 (white squares) only caused a significant shift in the V1/2 of voltage-dependence of steady-state fast inactivation at NaV1.2, NaV1.3, NaV1.4 and NaV1.9 compared to control (black squares). Imax is the maximal peak amplitude, determined for each cell, in the absence of the toxin. Data are presented as mean ± SEM, with n = 4–10 cells per data point.

Table 1: Effects of P-CTX-1 on NaV channel voltage dependence of activation and steady-state fast inactivation.

The effects of P-CTX-1 on the voltage-dependence of steady-state fast inactivation were less profound. A significant hyperpolarising shift was observed in the V1/2 for NaV1.2, NaV1.3 and NaV1.9, with a significant depolarising shift occurring only at NaV1.4 (ΔV1/2 inactivation: NaV1.1, −2.0 mV; NaV1.2, −6.9 mV; NaV1.3, −2.1 mV; NaV1.4, + 6.5 mV; NaV1.5, −0.5 mV; NaV1.6, −1.1 mV; NaV1.7, −2.0 mV; NaV1.8, −0.8 mV; NaV1.9, −10.6 mV; Fig. 2 and Table 1). P-CTX-1 had differential effects on NaV channel activation and inactivation kinetics, including significantly decreasing the time to peak at NaV1.2, significantly decreasing the inactivation time constant for NaV1.1, NaV1.2 and NaV1.3, and increasing the inactivation time constant for NaV1.8 (Fig. 3 and Table 2). P-CTX-1 also produced a significant persistent current at NaV1.3 (I/Imax, 3.4 ± 0.8%) and NaV1.8 (I/Imax, 7.6 ± 0.2%).

Figure 3: Representative effects of P-CTX-1 on NaV1.1–1.8 currents assessed by automated whole-cell patch clamping in mammalian cells.
Figure 3

Currents were elicited using a holding potential of −80 mV, followed by a pre-pulse of −100 mV for 50 ms and then a 50 ms pulse of −20 mV for NaV1.1–1.7 and +10 mV for NaV1.8. Black traces represent control current and grey traces represent current in the presence of P-CTX-1.

Table 2: Effects of P-CTX-1 on NaV channel activation and inactivation kinetics.

P-CTX-1 reduces the activation threshold of single NaV1.8 and NaV1.7 channels and lengthens their active periods

Our whole-cell measurements indicated that P-CTX-1 lowers the threshold for activation of NaV1.7 and NaV1.8, two key isoforms contributing to action potential generation and propagation in nociceptive neurons (Fig. 2, Table 1). However, in the presence of P-CTX-1, currents mediated by NaV1.8 channels inactivated with a slower time constant than those mediated by NaV1.7 (Fig. 3, Table 2). We thus used single channel recordings to further investigate how P-CTX-1 potentiated NaV1.7 and NaV1.8 by measuring single channel current amplitude and the duration of single channel active periods (activations).

Excised outside-out membrane patches expressing NaV1.8 channels were subjected to an activating voltage step of −100 mV to −20 mV (Fig. 4). At −100 mV, channel activations were too infrequent for any reliable analysis (Fig. 4a). However, depolarising the patch to −20 mV elicited brief bursts of single NaV1.8 channel openings. Multiple amplitude levels were discernible at −20 mV, the predominant ones being a large (1.36 ± 0.03 pA; duration 0.8 ± 0.2 ms) and a small (0.63 ± 0.04 pA; duration 10.5 ± 1.0 ms) amplitude opening. After exposure to P-CTX-1 (1 nM), significant channel activity at both amplitude levels was observed at −100 mV and −20 mV (Fig. 4b). The two amplitudes were slightly larger at −100 mV (1.64 ± 0.08 and 0.69 ± 0.05 pA) than at −20 mV (1.43 ± 0.04 pA and 0.63 ± 0.02 pA), reflecting the difference in driving force (in the absence of Na+ in the pipette solution), but were essentially unchanged in the presence of P-CTX-1. However, P-CTX-1 did produce dramatic effects on the duration of single channel activations (Fig. 4b and c). At −100 mV, the mean duration of the large channel activations was substantially longer (1357 ± 122 ms) than at −20 mV (3.6 ± 0.8 ms), lasting over 5 s in some patches (Fig. 4c). Conversely, the duration of the smaller amplitude activations were enhanced more at −20 mV (1821 ± 138 ms) than at −100 mV (165 ± 14 ms; Fig. 4d).

Figure 4: Effect of P-CTX-1 on single channel activity of NaV1.7 and NaV1.8.
Figure 4

(a) Single channel activity recorded from a membrane patch expressing Nav 1.8 channels after depolarising the membrane from −100 mV to −20 mV (shown above). Two main amplitudes were apparent, but only at −20 mV. These are boxed in red and shown on an expanded time scale below. (b) A similar activation protocol was applied to a recorded patch after exposing it to 1 nM P-CTX-1 for 10 minutes. Note the presence of activity at −100 mV and −20 mV of both amplitude levels. Areas boxed in red are shown below on an expanded time scale. (c) Continuous recording from a patch exposed to 1 nM P-CTX-1 for 10–12 minutes at −100 mV showing long activation periods, interrupted by brief inactivity, likely corresponding to channel inactivation. The two lower current traces are from the same patch but on an expanded time scale. (d) Summary plots of the mean durations of activations before (Ctrl) and after (P-CTX-1) exposure to P-CTX-1 for activations at both amplitude levels. (e) Single channel recordings from a patch expressing NaV 1.7 channels, showing negligible activity at −100 mV, but significant activity at −20 mV. The sections boxed in red are shown below at a higher temporal resolution. (f) After exposing the recorded path to 1 nM P-CTX-1 for 10 minutes the channels exhibited frequent openings at −100 mV, but less activity at −20 mV. Selected sections are boxed in red and shown at higher temporal resolution below. (g) Sample currents after exposure to P-CTX-1 at −100 mV at two temporal resolutions (above) and control sweeps (black) and after P-CTX-1 exposure (green) at −20 mV, showing a reduction in channel activity. (h) Summary plots of the mean durations of activations before (Ctrl) and after (P-CTX-1) exposure to P-CTX-1 for activations at both amplitude levels.

The above experiments were repeated on excised membrane patches expressing NaV1.7 channels. At −100 mV, NaV1.7 channels were mostly inactive, whereas stepping the membrane potential to −20 mV elicited short-lived channel openings (Fig. 4e) of similar amplitude to those mediated by NaV1.8 channels. Again, two main amplitudes were discernible. The larger amplitude was predominant (>90% of openings, amplitude 1.28 ± 0.03 pA, duration 3.1 ± 0.2 ms), whereas the smaller amplitude openings were rarely observed (<10% of openings, amplitude 0.74 ± 0.03 pA, duration 1.6 ± 0.1 ms). After exposure of the recorded patches to P-CTX-1, significant activity was observed at −100 mV (Fig. 4f and g), however, at −20 mV the frequency of openings was markedly reduced compared with control (Fig. 4f). As for the NaV1.8 channels, both the larger and smaller NaV1.7 amplitude openings were relatively unaffected by P-CTX-1 at either −100 mV (larger amplitude, 1.67 ± 0.03 pA; smaller amplitude, 0.87 ± 0.03 pA) or −20 mV (larger amplitude, 1.31 ± 0.04 pA; smaller amplitude 0.75 ± 0.03 pA). In contrast to NaV1.8, P-CTX-1 had relatively minor effects on the mean durations of NaV1.7 single channel activity, which were increased for larger (5.3 ± 0.9 ms mean duration) and smaller (9.5 ± 2.5 ms mean duration) amplitudes at −100 mV. At −20 mV the mean durations for large and small amplitude openings were 3.3 ± 0.4 ms and 3.6 ± 0.9 ms, respectively (Fig. 4h).

The single channel experiments confirmed that the effects of P-CTX-1 on NaV1.8 substantially differ from effects on NaV1.7. The most apparent common effect of P-CTX-1 on NaV1.7 and NaV1.8 was a decrease of the threshold of activation to a level where the channels are not normally active (−100 mV). This effect also manifests in the whole-cell data, with a decrease in the V1/2 for activation for both subtypes (Table 1). Although P-CTX-1 generally lengthened the periods of discrete single channels activations in both subtypes, the effect on NaV1.8 was substantially greater. The P-CTX-1-induced increase in the duration of the activations likely underlies the significant increase in the inactivation time constant of ensemble currents (Table 2).

Contribution of NaV isoforms to P-CTX-1-induced responses of sensory dorsal root ganglion neurons

As individual sensory neurons can express multiple NaV isoforms, we next assessed the relative contribution of TTX-s and TTX-r NaV isoforms to P-CTX-1-induced responses using fluorescent live cell imaging of cultured dorsal root ganglion (DRG) neurons. At a concentration of 5 nM, P-CTX-1 elicited Na+ influx in most DRG neurons, albeit the size of the responses varied considerably (Fig. 5a). Consistent with the observed effect on the electrophysiological properties of NaV1.8, P-CTX-induced Na+ influx was significantly decreased in DRG neurons from NaV1.8−/− animals (Control (ΔF), 1285 ± 15; NaV1.8−/− (ΔF), 1140 ± 8; p < 0.001, Fig. 5a). Nevertheless, many individual cells still responded with large increases in intracellular Na+ to application of P-CTX-1. Similarly, treatment of DRG neurons with TTX (1 μM) significantly decreased P-CTX-1-induced responses compared with control, although several cells with large responses remained, supporting an important contribution of both TTX-s and TTX-r isoforms to the enhanced sensory neuronal excitability induced by P-CTX-1 (Control (ΔF), 1285 ± 15; TTX (ΔF), 1138 ± 19; p < 0.001, Fig. 5a). Exposure of DRG neurons from NaV1.8−/− animals to TTX (1 μM) further decreased responses (NaV1.8−/− + TTX (ΔF), 1050 ± 23, p < 0.01, Fig. 5a), although some small responses remained. Whilst overall, Na+ influx was not significantly changed in DRGs from NaV1.9−/− animals (NaV1.9−/− (ΔF), 1310 ± 25, p > 0.01, Fig. 5a), the presence of small P-CTX-1-evoked responses in NaV1.8−/− DRG neurons treated with TTX indicates that NaV1.9 contributes to P-CTX-1-induced Na+ influx in some cells (Fig. 5a).

Figure 5: P-CTX-1 induced responses in isolated dorsal root ganglion neurons.
Figure 5

(a) Increases in intracellular Na+ in response to P-CTX-1 (1 nM) were assessed in dissociated DRG neurons from wild-type, NaV1.8−/− and NaV1.9−/− mice in the absence and presence of TTX (1 μM). P-CTX-1-induced responses were significantly (*P < 0.0001) decreased in DRGs from NaV1.8−/−, but not NaV1.9 −/− mice and after treatment with TTX. Data is presented as mean ± SEM from n = 51–163 cells/group. (b) Increases in intracellular Ca2+ in response to P-CTX-1 (1 nM) were assessed in dissociated DRG neurons from wild-type mice in the absence and presence of TTX (1 μM). P-CTX-1-induced responses were significantly decreased in DRG neurons co-incubated with TTX (*P < 0.0001). Data is presented as mean ± SEM from n = 49 neurons (P-CTX-1) and n = 57 neurons (P-CTX-1 + TTX). (c) P-CTX-induced activation of intracellular Ca2+ within identified colonic DRG neurons. Note that 1 nM P-CTX-1 induced a different magnitude of responses (small, medium and large). TTX (0.5 μM) reduced P-CTX-1-induced activation of colonic DRG neurons. This reduction was specially marked in colonic neurons exhibiting large responses when co-incubated with TTX. Data is presented as mean ± SEM from n = 18 colonic DRG neurons (P-CTX-1) and n = 12 colonic DRG neurons (P-CTX-1 + TTX). *P < 0.0001 using One-way ANOVA (a) or student’s t-test (b,c).

As a secondary process to Na+ channel activation, we also assessed P-CTX-1 induced Ca2+ influx in DRG neurons. Similar to what we observed with Na+ entry, P-CTX-1 (1 nM) elicited Ca2+ influx in most DRG neurons with considerable variability in the size and magnitude of the responses (Fig. 5b). Treatment with TTX (1 μM) significantly decreased P-CTX-1-induced Ca2+ responses compared with control P-CTX-1 response (*p < 0.0001), although several large responses remained. This further supports an important contribution of both TTX-s and TTX-r isoforms to the enhanced sensory neuronal excitability induced by P-CTX-1.

As the early signs of ciguatera include gastrointestinal symptoms such as abdominal pain, we tested P-CTX-1 on DRG neurons that specifically innervate the colon. We found that P-CTX-1-induced Ca2+ responses were qualitatively similar in colonic sensory neurons to those in non-colonic neurons (Fig. 5c), with 83.3% (15/18) of colonic DRG neurons activated by P-CTX-1. The size of the responses also varied considerably including small (46.8% of all activated neurons), medium (26.7% of all activated neurons) and large (26.7% of all activated neurons) magnitude responses (Fig. 5c). TTX (0.5 μM) reduced the number of colonic DRG neurons activated by P-CTX-1 to 58.3% (7/12), and also reduced the magnitude of Ca2+ influx induced by P-CTX-1 (Fig. 5c). The P-CTX-1-induced large magnitude responses in colonic neurons appeared to be predominantly mediated by TTX-s channels (Fig. 5c), as only 5% (1 out of 18) of colonic DRG neurons responded to P-CTX-1 when co-incubated with TTX compared with 33% (4 out 12) of colonic DRG neurons with large responses induced by P-CTX-1 alone.

P-CTX-1 evokes action potential firing in dermal and colonic sensory afferents

To further pharmacologically explore the contribution of individual NaV subtypes to enhanced excitability induced by P-CTX-1, we recorded propagated action potentials from single receptive fields of sensory afferents, recorded extracellularly from murine skin-saphenous nerves and from colonic splanchnic nerves.

In the murine skin-saphenous nerve preparation, P-CTX-1 (0.5 nM) induced action potential firing in all previously quiescent C fibres (12/12), with some fibres exhibiting a modest increase in activity (4/12 fibres; <50 action potentials/5 min) (Fig. 6a). Consistent with our previous findings9, action potential firing induced by P-CTX-1 in the skin was mediated predominantly by TTX-r NaV isoforms in C-fibres, as treatment with the selective NaV1.7 inhibitor Pn3a23 (1 μM, Suppl Fig. 1), the NaV1.6 inhibitor GIIIA (10 μM), or TTX (1 μM) did not significantly decrease action potential firing overall (p > 0.05, Fig. 6a). However, some individual fibres (4/12) were silenced after inhibition of TTX-s NaV isoforms (Fig. 6b). Notably, the P-CTX-1-induced firing frequency of these fibres was modest (action potentials/5 min: 53.2 ± 40.6) in comparison with fibres that were unaffected by TTX (action potentials/5 min: 166.1 ± 66.6). Similar to our previous findings using recordings from NaV1.8−/− animals9, where P-CTX-1-induced firing in C-fibres was markedly decreased, the NaV1.8 inhibitor A803467 (10 μM; p < 0.05) significantly decreased action potential firing frequency by 62.8 ± 15.5% (Fig. 6c).

Figure 6: P-CTX-1 induces spontaneous action potential firing in peripheral sensory afferents.
Figure 6

(a) Effect of P-CTX-1 (0.5 nM) on single C-fibres recorded from a skin-saphenous nerve preparation in the mouse. Selective inhibitors of NaV1.7 (Pn3a, 1 μM); NaV1.6 (GIIIA, 10 μM), TTX-s NaV isoforms (TTX, 1 μM) and NaV1.8 (A803467, 10 μM) were sequentially perfused at the receptive field to assess cumulative effects of NaV inhibition on action potential firing. Each data point represents the number of action potentials/5 min from a single C-fibre receptive field. (b) Representative recording of a C-fibre silenced by the selective NaV1.7 inhibitor Pn3a (1 μM). (c) Representative recording of a C-fibre unaffected by Pn3a (1 μM), GIIIA (10 μM) and TTX (1 μM) and silenced by the NaV1.8 inhibitor A803467 (10 μM). (d) Effect of P-CTX-1 (0.5 nM) on single A-fibres recorded from a skin-saphenous nerve preparation in the mouse. Selective inhibitors of either NaV1.7 (Pn3a, 1 μM) or NaV1.6 (GIIIA, 10 μM) almost completely silenced P-CTX-1-induced action potential firing in A-fibres. Each data point represents the number of action potentials/5 min from a single A-fibre receptive field. (e) Representative recording of an A-fibre silenced by Pn3a (1 μM) and (f) GIIIA (10 μM). (b,c and e,f) Each data point represents a single action potential and is plotted as a function of instantaneous frequency (1/s) to represent the time elapsed since the previous action potential. Arrows indicate time points of superfusion with compounds. (g) P-CTX-1 (1 nM) is a potent activator of colonic nociceptors (activating 14/19 afferents) and also recruits silent afferents (9/19 afferents). (h) Pre-incubation with the NaV1.8 blocker A803467 (10 μM for 15 min) prevents P-CTX-1-induced firing of colonic nociceptors (7/7 afferents tested). Data are presented as mean ± SEM. Statistical significance was determined using (a) One-way ANOVA with Friedman post-hoc test or (d) student’s matched observations t-test and defined as p < 0.05 (*).

In contrast, P-CTX-1 elicited action potential firing in only 44.8% (13/29) of A-fibres, with responding fibres displaying significantly (p < 0.05) slower conduction velocities (6.28 ± 0.95 m/s, n = 6) than non-responders (10.64 ± 1.50 m/s, n = 5). Inhibition of the TTX-s isoforms NaV1.6 or NaV1.7 had a profound effect on action potential firing in A-fibres, with both Pn3a and GIIIA almost completely silencing P-CTX-1-induced activity (Fig. 6d). Interestingly, inhibition of either NaV1.7 (Fig. 6e) or NaV1.6 (Fig. 6f) appeared to be sufficient to virtually abolish spontaneous action potential firing, suggesting that both channels act in concert to maintain P-CTX-1-induced ongoing activity. Thus, both TTX-s and TTX-r isoforms contribute to the enhanced excitability of peripheral sensory neurons caused by P-CTX-1, albeit with their relative contributions differing between fibre types.

Unlike skin afferents, all colonic afferents have conduction velocities in the C-fibre range24,25. Using an ex-vivo colonic afferent preparation, we investigated the effects of P-CTX-1 on colonic nociceptive afferents that respond at noxious levels of distension or high intensity circular stretch and are therefore likely to signal “nociceptive” events26. We found that P-CTX-1 (1 nM) potently activated 74% of colonic nociceptors (14/19) as well as recruiting a population of ‘silent nociceptors’ (47%, 9/19 preparations) (Fig. 6g). Consistent with the results on C-fibres in the skin-nerve preparation, incubation with the NaV1.8 inhibitor A803467 (10 μM) abolished P-CTX-1-induced action potential firing in all colonic nociceptors tested (7/7) (Fig. 6h).

Multiple sodium channel isoforms mediate the in vivo actions of P-CTX-1

We recently established an animal model of ciguatera based on the intraplantar administration of P-CTX-1 in mice and showed that ciguatoxin-induced cold allodynia is mediated through TRPA1-expressing C-fibres and involves NaV1.89. However, whilst we have shown that both TTX-s and TTX-r NaV isoforms contribute to increased neuronal excitability evoked by P-CTX-1, the relative contribution of NaV1.1–1.9 to the symptomatology of ciguatera remains unresolved. We thus sought to assess the in vivo contribution of individual NaV isoforms to P-CTX-1-induced pain and gastrointestinal effects in relevant murine models.

P-CTX-1-induced spontaneous dermal pain behaviours are mediated by NaV1.6 and NaV1.7

Cold allodynia is a pathognomonic symptom of ciguatera and occurs in up to 94% of ciguatera sufferers. However, ciguatera is also associated with a number of non-thermally evoked painful dysaesthesias attributable to the direct effects of ciguatoxin on NaV channels expressed on peripheral sensory neurons, including arthralgias, myalgias, proctalgia, odontalgia, dysuria and dyspareunia. Indeed, intracutaneous administration of P-CTX-1 in humans elicits an axon reflex flare and spontaneous pain; effects that also occur after intraplantar administration of P-CTX-1 in mice9,27. In order to determine the NaV isoforms contributing to the ciguatoxin-induced in vivo effects, we first assessed the effect of local administration of TTX (2 μM) on P-CTX-1-induced dermal pain behaviours. To enable assessment of TTX effects on both spontaneous pain behaviours as well as cold allodynia, we first administered P-CTX-1 (10 nM; 20 μl) by intraplantar injection and assessed nocifensive behaviours at 32 °C for 10 min. A subsequent intraplantar injection of TTX (2 μM, 20 μl; 6.6 ± 3.9 flinches/5 min) almost completely reversed spontaneous pain behaviours compared with intraplantar injection of saline (20 μl; 96.2 ± 8.5 behaviours/5 min) but only partially reversed cold allodynia assessed at 15 °C (Saline, 67.8 ± 10.1 behaviours/5 min; TTX, 35.8 ± 7.1 behaviours/5 min) (Fig. 7a). Consistent with the profound effect of TTX, which was also observed when co-administered with P-CTX-1 (5 nM, 40 μl, 95.6 ± 9.1 behaviours/5 min; TTX (1 μM), 7.1 ± 1.3 behaviours/5 min; p < 0.01), treatment with the NaV1.8 inhibitor A803467 (10 μM, 105.7 ± 9.4 behaviours/5 min) had no effect on P-CTX-1-induced pain behaviours (Fig. 7b). Similarly, P-CTX-1-induced pain behaviours were also unchanged after co-administration of the NaV1.1/1.2 inhibitor TIIIA (10 μM; 125.7 ± 31.1 behaviours/5 min), while intraplantar administration of the NaV1.6 inhibitor GIIIA (10 μM; 19.0 ± 10.1 behaviours/5 min; p < 0.01) significantly reduced P-CTX-1-induced pain behaviours (Fig. 7b). In addition, the selective NaV1.7 inhibitor Pn3a (3 μM; 7.7 ± 5.7 behaviours/5 min; p < 0.01) was also effective at reducing ciguatoxin-induced pain behaviours (Fig. 7b). Overall, these data suggest that the P-CTX-1 effects on TTX-s NaV isoforms, in particular NaV1.6 and NaV1.7, are associated with symptoms of spontaneous (non-stimulus-induced) pain, while TTX-r isoforms contribute to cold allodynia.

Figure 7: Multiple NaV isoforms mediate the in vivo effects of P-CTX-1.
Figure 7

(a) Intraplantar injection of P-CTX-1 in C57BL/6 mice causes spontaneous pain behaviours at 32 °C which are completely blocked by local administration of TTX (2 μM). Cold allodynia evoked at 15 °C is partially reduced by TTX. (n = 5/group) (b) At ambient temperature, P-CTX-1-induced nocifensive behaviours were significantly decreased by co-administration of TTX (1 μM), the selective NaV1.7 inhibitor Pn3a (3 μM) and the NaV1.6 inhibitor GIIIA (10 μM), but not the NaV1.8 inhibitor A803467 (10 μM) or the NaV1.1/1.2 inhibitor TIIIA (10 μM). (n = 4–12 animals/group). (c) In vivo intra-colonic administration of P-CTX-1 (1 nM) activates nociceptive endings within the wall of the colon, leading to signalling into the dorsal horn and activation of neurons within the thoracolumbar spinal cord, as identified by pERK immunoreactivity (arrows). pERK-IR neurons were predominantly located in the nociresponsive superficial dorsal horn (laminae I) and also in laminae V. (d) Intracolonic administration of vehicle alone did not induce dorsal horn neuron pERK immunoreactivity. (e) Group data showing that P-CTX-1 evoked significant dorsal horn neuron activation (**p < 0.005) compared with vehicle administered mice (n = 3–4 animals/group). (f–m) A novel mouse model of P-CTX-1-induced visceral pain. Intracolonic administration of P-CTX-1 (50 μl, 10 nM) caused a significant (*p < 0.05 compared with Saline control) increase in (f) still and (g) grooming behaviours as well as a significant (*p < 0.05 compared with Saline control) decrease in (h) orienting, (i) rearing, (k) walking, (l) trotting and (m) running. These behavioural changes were reversed by A803467 (100 mg/kg; #p < 0.05 compared with P-CTX-1) but not intracolonic TTX (100 nM). (n = 6–12 animals/group) (n) NaV1.8 is the most highly expressed NaV isoform in whole thoracolumbar DRG (n = 5 animals/target). (o) NaV1.8 is highly expressed within thoracolumbar DRG neurons innervating the colon (88%: 21 out of 24 colonic neurons). Data are presented as mean ± SEM. Statistical significance (defined as p < 0.05) was determined using student’s t-test (a,e) or One-way ANOVA with Sidak’s multiple comparison (b,f–m).

Ciguatoxin-induced gastrointestinal sensory disturbances are mediated predominantly by NaV1.8

In order to delineate the NaV isoforms contributing to ciguatoxin-induced gastrointestinal disturbances, we established a model of P-CTX-1-induced abdominal pain. Consistent with the excitatory effect of P-CTX-1 on colonic nociceptors (Fig. 6g,h), intracolonic administration of P-CTX-1 (1 nM, 100 μl) resulted in the activation of dorsal horn neurons within the thoracolumbar spinal cord, as identified by pERK immunoreactivity (Fig. 7c). There was a significantly greater number of pERK-IR neurons following intracolonic P-CTX-1 compared to vehicle (Fig. 7d,e). The pERK-IR neurons activated by P-CTX-1 are primarily located within the superficial dorsal horn laminae I and V, indicating the activation of nociceptive processing pathways within the spinal cord. In order to evaluate behavioural changes associated with intracolonic administration of P-CTX-1, we assessed exploring and grooming behaviours using an automated rodent behavioural analysis platform (Behavioral Spectrometer, Biobserve, New Jersey, USA). Compared with administration of saline, intracolonic P-CTX-1 led to a significant increase (p < 0.05) in still (Fig. 7f) and grooming (Fig. 7g) behaviours as well as a significant decrease (p < 0.05) in orienting (Fig. 7h), rearing (Fig. 7i), walking (Fig. 7k), trotting (Fig. 7l) and running (Fig. 7m). As the selective NaV1.8 inhibitor A803467 blocked P-CTX-1-induced action potential firing of colonic nociceptors in our ex vivo preparation (Fig. 6), we tested the effect of A803467 on changes in P-CTX-1-induced behaviours. Consistent with a major role for TTX-r isoforms, specifically NaV1.8, in visceral pain, A803467 significantly reversed all behavioural deficits, while concomitant intracolonic administration of TTX (100 nM) did not fully reverse P-CTX-1-induced behaviours (Fig. 7f–m).

To gain further insight into the mechanisms underlying the dominant role of NaV1.8 in mediating the P-CTX-1-induced visceral effects, we next assessed expression of NaV1.6, NaV1.7 and NaV1.8 in whole thoracolumbar (TL) DRG (Fig. 7n) and found that NaV1.8 was the most highly expressed NaV isoform, followed by NaV1.7 and NaV1.6. Single cell RT-PCR expression analysis within individual retrogradely labelled colonic DRG neurons revealed that NaV1.6 was expressed in 63% (15/24), NaV1.7 expressed in 100% (24/24) and NaV1.8 expressed in 88% (21/24) of thoracolumbar colonic DRG neurons (Fig. 7o). Thus, the high and nearly ubiquitous expression of NaV1.8 in colonic DRG neurons provides an explanation for the apparent functional selectivity of an essentially non-selective NaV activator toxin like P-CTX-1.

Discussion

Ciguatera is a circumtropical ichthyosarcotoxism linked to the consumption of fish contaminated by the ciguatoxins; heat-stable polyethers that activate neuronal NaV isoforms to cause neuronal hyper-excitability. The disease is endemic in the Pacific, Caribbean and Indian Oceans and presents with predominantly gastrointestinal and sensory disturbances, muscle weakness, as well as cardiovascular effects in severe poisonings1. While it is established that these manifestations of ciguatoxin poisoning are likely attributable to activation of NaV isoforms expressed in sensory neurons, cardiac tissue and skeletal muscle, the effects of ciguatoxin on individual NaV isoforms and their relative contribution to the symptomatology of ciguatera has not been assessed systematically. Therefore, we determined the specific effects of P-CTX-1 on all NaV isoforms, as well as the contribution of individual NaV isoforms to action potential firing in dermal and visceral afferents. We also determined the NaV isoforms contributing to ciguatoxin-induced pain of dermal and gastrointestinal origin. Overall, our results suggest that the effects of P-CTX-1 on NaV1.8 are particularly important in the majority of C-fibre nociceptors, while TTX-s NaV isoforms, in particular NaV1.6 and NaV1.7, contribute to P-CTX-1-mediated effects on A-fibres.

P-CTX-1 is the most potent ciguatoxin congener and is thought to be responsible for the majority of symptoms in the Pacific28. Ingestion of fish contaminated with 0.1 ppb ciguatoxin is known to cause ciguatera, with the average pathogenic dose causing symptoms in humans estimated at 2 ng/kg29. In mice, intravenous dosing with 130 ng/kg P-CTX-1 was associated with peak plasma levels of approximately 60 pg/mL30, however unfortunately, data on plasma ciguatoxin levels in human ciguatera patients is not available.

Estimation of the concentration of the ciguatoxins in tissue is even more difficult, particularly in light of the high lipophilicity of the toxins and the corresponding large volume of distribution31. Based on human experiments assessing sensory effects of P-CTX-1 after intracutaneous administration, concentrations ranging from 1–10 nM are sufficient to elicit symptoms of itching, burning pain and cold allodynia9,27. Given the rapid emergence of effects after local administration, as well as the quasi-irreversible binding to NaV channels, losses due to redistribution are likely minimal, suggesting that the concentrations of P-CTX-1 used for in vitro studies in our experiments are highly relevant to human disease.

We found that P-CTX-1 is approximately equipotent at all human NaV isoforms. Although P-CTX-1 can be considered a relatively non-selective NaV activator in terms of potency, we did observe significant functional differences that were NaV subtype dependent.

While the voltage-dependence of activation was shifted to more hyperpolarising potentials at all NaV subtypes, a hyperpolarising shift in the voltage-dependence of steady-state fast inactivation only occurred at NaV1.2, NaV1.3 and NaV1.9. These observed hyperpolarising shifts could lead to decreased availability of these isoforms for action potential generation and propagation in vivo. In addition, P-CTX-1 induced a significantly accelerated inactivation at NaV1.1, NaV1.2 and NaV1.3. In contrast, a significant depolarising shift in steady-state fast inactivation was observed for NaV1.4. Similar effects were also reported for the N440K NaV1.4 mutation, which is associated with paradoxical myotonia32, suggesting that the increase in window current effected by concomitant shifts in the voltage-dependence of activation and inactivation of NaV1.4 may contribute to ciguatoxin-induced muscle weakness.

P-CTX-1 also caused a small persistent current at NaV1.3, which may contribute to the slightly increased activity at this isoform we observed in the membrane potential assay. This activity may also explain our previous observation that P-CTX-1-induced responses in the neuroblastoma cell line SH-SY5Y are mediated predominantly through NaV1.327. However, as NaV1.3 is typically expressed at high levels during development, and is reported to be essentially absent from adult rodent DRG neurons, this suggests that effects at NaV1.3 are unlikely to contribute substantially to the in vivo symptomatology of ciguatera33. Interestingly, a previous study reporting the emergence of a TTX-sensitive leak current after treatment with P-CTX-1 used neonatal DRGs, suggesting that this activity may have been mediated by expression of neonatal NaV1.320.

P-CTX-1 had the most pronounced effects at NaV1.8, including a large shift in the voltage-dependence of activation that was particularly apparent at depolarised potentials, and a significant delay in inactivation. In contrast, P-CTX-1 did not affect the voltage-dependence of fast inactivation of NaV1.8. These effects are consistent with our observation of increased activation and prolonged active periods observed with single channel recordings, and the reported effects of the synthetic ciguatoxin analogue CTX3C on rat NaV1.8 channels, where large leak currents as well as a shift in the voltage-dependence of activation occurred, albeit at 10-fold higher concentrations and bringing into question whether the native form of CTX3C was synthesised34.

The binding site of the ciguatoxins and brevetoxins, all of which are believed to act at site 5 of the voltage-gated sodium channel35,36, is relatively poorly defined. Using elegant photoaffinity labelling experiments of rat brain sodium channels, the likely regions involved in binding of brevetoxin were identified as residues in domain I S6 (Thr400-Lys443; rat NaV1.2 numbering) and the extracellular loop following domain IV S5 (Glu1688 – Lys1735; rat NaV1.2 numbering)35.

The domain I binding site appears to be particularly important for high affinity effects of the ciguatoxins on NaV1.8, as chimeric channels containing domains I and II from NaV1.4 responded much less to synthetic ciguatoxin analogues than native NaV1.8, or chimeras incorporating domains I and II from NaV1.834. Interestingly, both the domain I and domain IV regions are highly conserved across rodent and human NaV isoforms, perhaps explaining at least in part the essentially non-selective effects of P-CTX-1. More subtle, subtype-specific effects on channel gating are more difficult to explain with our current knowledge of the ciguatoxin binding site. For example, the residues forming site 5 in domain I are identical between human NaV1.1 and NaV1.2, while only 2 residues (G1727 > K and D1734 > N, NaV1.2 numbering) differ in domain IV. It is currently unclear whether these differences could contribute to the observed effect of P-CTX-1 on channel inactivation at NaV1.2, but not NaV1.1. An alternate, perhaps more likely, explanation is that additional, as yet undefined, residues outside the immediate binding pocket contribute to subtype-specific effects on channel gating.

Adult sensory neurons predominantly express three TTX-sensitive NaV isoforms NaV1.1, NaV1.6, and NaV1.7, as well as the TTX-resistant isoforms NaV1.8 and NaV1.937,38. Previous studies have demonstrated that P-CTX-1 affects both TTX-sensitive and TTX-resistant NaV isoforms in DRG neurons20,21. Accordingly, in the current study using cultured DRG neurons, both NaV1.8 and TTX-sensitive isoforms were major contributors to P-CTX-1-induced responses. However, while P-CTX-1 also affected the voltage-dependence of activation of NaV1.9, P-CTX-1-induced responses were unchanged in DRG neurons from NaV1.9−/− animals. Nonetheless, some small responses remained in DRG neurons from NaV1.8−/− animals treated with TTX, suggesting that at least a small component of Na+ influx induced by P-CTX-1 may be conducted by NaV1.9. Indeed, a small number of non-responding individual neurons were observed in cultures from NaV1.9−/− animals. These results suggest that, at least at the concentrations assessed here, and perhaps due to CTX’s effects on voltage-dependence of fast inactivation, NaV1.9 is not a major contributor to P-CTX-1-mediated effects.

Experiments assessing P-CTX-1-induced action potential firing in C-fibres both from the skin-saphenous nerve and colonic preparations revealed a major role for NaV1.8, with the NaV1.8 blocker A803467 significantly reducing or blocking firing. While some dermal C-fibres were silenced by TTX, surprisingly few were affected by selective inhibition of NaV1.7, suggesting that in the majority of C-fibres, P-CTX-1-induced action potential firing is maintained by NaV1.8. This observation is consistent with previous studies reporting a contribution of NaV1.8 to more than 80% of the inward membrane current during the rising phase of the action potential39 and also a substantial decrease in C-fibre activity in response to P-CTX-1 in fibres from NaV1.8−/− mice9. In terms of visceral pathways, the involvement of NaV1.8 in P-CTX-1 induced colonic nociceptor activation is consistent with a pronounced role for NaV1.8 in visceral pain, as demonstrated by Nav1.8 −/− mice displaying blunted pain and hyperalgesia to intracolonic mustard oil administration40.

We found that P-CTX-1-induced action potential firing in A-fibres was almost completely abolished by selective inhibition of NaV1.7 and substantially reduced by the NaV1.6 inhibitor GIIIA. These findings are consistent with the major contribution of TTX-s NaV isoforms to action potential conduction in these neurons41,42. The NaV1.7 findings are intriguing, as NaV1.7 plays a key role in regulating sensory neuron excitability, owing to its unique expression pattern, as well as slow closed-state inactivation, which underpins the ability of NaV1.7 to generate large ramp currents in response to slow depolarisations43. While we could not assess expression of NaV1.7 in non-responding A-fibres, and distinction of Aβ and Aδ fibres based on conduction velocity is difficult in the murine skin-nerve preparation due to the limited length of the saphenous nerve, it seems plausible that nerve endings of Aδ fibres expressing NaV1.7 respond to P-CTX-1 with action potential firing, whereas those lacking this isoform (presumably Aβ fibres) do not. This conclusion is not only consistent with the hyperpolarising shift in the voltage-dependence of activation at NaV1.7 caused by P-CTX-1, which would lead to enhanced neuronal excitability and action potential firing, but also expression of NaV1.7 in a significant proportion of high- and low-threshold myelinated Aδ neurons but few, if any, cutaneous myelinated Aα/β low-threshold mechanosensitive units44. Indeed, our results showed that A-fibres responding to P-CTX-1 had slower conduction velocities than non-responders. In comparison, NaV1.6 is widely expressed in large diameter DRG neurons of myelinated fibres, where it is localised predominantly at the nodes of Ranvier45,46. Thus, the selective activation of some, but not all, A-fibres by P-CTX-1 suggests that the relatively minor shift in the voltage-dependence of activation at NaV1.6 caused by P-CTX-1 is not sufficient to induce action potential firing, and that the inhibitory actions of GIIIA likely arises from the effects on action potential propagation, which depends on NaV1.6 in these fibres.

We have previously shown in humans that the in vivo effects of P-CTX-1 after intradermal injection closely resemble the effects elicited by intraplantar injection in mice. This is evidenced by characteristic symptoms of spontaneous pain that resolve to reveal cold allodynia upon exposure to cool temperatures9,27. Whilst P-CTX-1-induced cold allodynia is mediated by TRPA1-expressing nociceptors and involves activation of NaV1.8, the contribution of individual NaV isoforms to P-CTX-1-induced spontaneous and visceral pain have not been determined. In the current study we found that inhibition of P-CTX-1-induced acute dermal pain paralleled the pharmacology of action potential firing in A-fibres, with both selective NaV1.7 and NaV1.6 inhibition leading to a reversal of associated pain behaviours. This likely reflects the pattern of expression of NaV isoforms in the sensory nerve endings of skin afferents47, which in turn is determined by the electrophysiological properties of individual isoforms, as well as the specific effects of P-CTX-1 on each isoform. Accordingly, in colonic sensory neurons, where NaV1.8 was the most highly expressed isoform, inhibition of NaV1.8 by A803467, a subtype-selective small molecule blocker, significantly reversed P-CTX-1-induced behavioural effects.

In terms of other NaV isoforms expressed by DRG neurons, NaV1.1 was recently shown to mediate mechanically-evoked action potential firing in dermal and colonic sensory neurons48. While P-CTX-1 caused a hyperpolarising shift in the voltage-dependence of NaV1.1 activation, it also caused acceleration of inactivation, suggesting that the contribution of NaV1.1 to P-CTX-1-induced in vivo effects may be negligible. Indeed, we previously reported a lack of P-CTX-1-induced mechanical allodynia after intraplantar injection9, consistent with the lack of effect of the NaV1.1 inhibitor TIIIA on spontaneous pain observed in this study.

While intraperitoneal injection of P-CTX-1 gives rise to symptoms consistent with visceral hypersensitivity, including diarrhoea, writhing and abdominal contractions, potentially confounding effects on global nerve conduction velocity make it poorly suited to delineating the pharmacology of ciguatoxin-induced visceral pain49,50. In contrast, our model based on intracolonic administration of P-CTX-1, which caused activation of colonic nociceptors and activation of nociceptive processing regions in the spinal cord, led to more subtle effects on behaviour, including decreased locomotion and exploring behaviours. However, while systemic dosing with the NaV1.8 inhibitor A803467 led to a substantial decrease in P-CTX-1-induced behavioural abnormalities, the TTX-sensitive NaV isoforms contributing to the in vivo effects of ciguatoxin remain to be determined. A likely candidate is NaV1.7, albeit NaV1.1 was recently shown to contribute to visceral mechanical hypersensitivity in models of irritable bowel syndrome48. A particularly interesting aspect that remains to be addressed is whether oral administration of subtype-selective peptidic NaV inhibitors could ameliorate the gastrointestinal symptoms associated with ciguatera.

Finally, while this study focused on the subtype-selective effects of P-CTX-1 on NaV isoforms, the ciguatoxins are also known to inhibit K+ channel function. However, while effects on both delayed rectifier and A-type channels have been reported51, the pharmacology of P-CTX-1 at heterologously expressed K+ channel isoforms has not been systematically assessed. Accordingly, the contribution of this alternate pharmacology to the symptomatology of ciguatera remains to be determined, particularly since the subtle subtype-specific effects of NaV gating are unlikely to fully account for the pathognomonic symptom of cold allodynia.

In conclusion, we have shown that in terms of potency P-CTX-1 is a relatively non-selective activator of human NaV subtypes that shifts the voltage-dependence of activation to more hyperpolarising potentials for all NaV subtypes. However, P-CTX-1 induces distinct functional effects on NaV subtypes, including increasing the inactivation time constant at NaV1.8, increasing the slope factor of the conductance-voltage curve at NaV1.7, and increasing the peak current at NaV1.6. Correspondingly, the in vivo effects induced by P-CTX-1 appear to be driven predominantly by NaV1.6, NaV1.7 and NaV1.8. Thus, we conclude that the behavioural effects associated with ciguatera reflect the expression pattern of NaV isoforms in peripheral nerve endings, as well as their CTX-induced contribution to membrane depolarisation, action potential initiation and propagation. Accordingly, selective inhibitors of NaV1.7 and NaV1.8, and to a lesser extent NaV1.6 which is also found in motor nerves, may be promising therapeutics for management of the symptomatology of ciguatera in the clinic.

Materials and Methods

Ethics and animals

Ethical approval for experiments involving animals was obtained from the local animal ethics committees at the University of Queensland, the University of Adelaide, the South Australian Health and Medical Research Institute (SAHMRI) and the University of Erlangen in accordance with local legislation. Experiments involving animals were conducted in accordance with the Animal Care and Protection Act Qld (2002), the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 8th edition (2013) and the International Association for the Study of Pain Guidelines for the Use of Animals in Research. Adult male C57BL/6, NaV1.8−/− and NaV1.9−/− mice (John N. Wood, University College London, London, UK; congenic to C57BL/6 or backcrossed for at least 6 generations on the C57BL/6 background, respectively) and their age-matched litter controls were used. All animals were genotyped using previously reported primers52,53.

Animals were randomly assigned to treatment groups using a stratified randomisation strategy and all assessors were blinded to genotype or treatment. General health and wellbeing was monitored daily and no animals were withdrawn from the study. Sample sizes of each experiment are detailed in the figure legends of the corresponding figure.

Chemicals and drugs

P-CTX-1 was isolated and purified from moray eel viscera to >95% purity as previously described by Lewis et al.28 and stored as a concentrated stock in 50% methanol/50% H2O. P-CTX-1 was diluted in relevant assay buffers in the presence of 0.1% bovine serum albumin Cohn Fraction V (BSA) (BioScientific, Kirrawee, NSW, Australia) to avoid losses to plastic surfaces. Veratridine was obtained from Ascent Scientific (Bristol, United Kingdom). All other reagents were obtained from Sigma Aldrich (Castle Hill, NSW, Australia) unless otherwise specified.

Cell Lines and culture

Stable human embryonic kidney cells (HEK293) constitutively expressing human NaV isoforms NaV1.1–1.8 (SB Biomedical, Glasgow, United Kingdom). These cells were routinely maintained in minimal essential medium (MEM) (Sigma-Aldrich, Australia) supplemented with 10% foetal bovine serum (FBS) (Bovogen Biologicals, France), 2 mM L-glutamine and selection antibiotics as recommended by the manufacturer. For electrophysiological studies, CHO cells stably expressing hNaV1.8 in a tetracycline-inducible system (Chantest, OH, USA) were cultured in Ham’s F-12 containing 10% v/v foetal bovine serum and selection antibiotics as recommended by the manufacturer. To induce hNaV1.8 expression, cells were cultured in the presence of tetracycline (1 μg/mL) for 24 h at 27 °C. All cell lines were grown in a humidified 5% CO2 incubator at 37 °C, grown to 70–80% confluence, and passaged every 3–4 days using TrypLE Express (Invitrogen). HEK293 stably expressing hNaV1.9 were generated and maintained by Icagen Inc. (Durham, NC, USA) as described54.

FLIPRTetra Membrane Potential Assay

Activity of P-CTX-1 and Pn3a at hNav1.1–1.8 was assessed using a fluorescent plate reader (FLIPRTetra) membrane potential assay as previously described55. In brief, cell lines (HEK293 Nav1.1–1.8) were plated on 384-well black-walled imaging plates (Corning) at a density of 10 000–15 0000 cells per well 48 hours before loading with 20 μL of red membrane potential dye (proprietary formulation) (Molecular Devices, Sunnyvale, CA). Cells were incubated with the membrane potential dye for 30 min at 37 °C before the addition of P-CTX-1 and veratridine or deltamethrin by the FLIPRtetra system. After the first addition (P-CTX-1), fluorescence was measured (excitation 515–545 nm; emission: 565–625 nm) for a period of 5 min to determine the effects of P-CTX-1 alone. Following this 5 min exposure, veratridine (5–20 μM) or deltamethrin (100 μM) was added and fluorescence was measured for a further 5 min. Data was recorded and converted to response over baseline using Screenworks 3.2.0.14. For concentration-response curves, maximum values from the response after addition of agonist were plotted against agonist concentration and a 4-parameter logistic Hill equation was fitted to the data using GraphPad Prism Version 6.00 (San Diego, CA).

Electrophysiology

Electrophysiology (NaV1.1–1.8)

For NaV1.1–1.8, whole-cell patch-clamp experiments were performed on a QPatch-16 automated electrophysiology platform (Sophion Bioscience, Ballerup, Denmark) using 16-channel planar patch chip plates (QPlates; Sophion Bioscience) with a patch hole diameter of 1 μm and resistance of 2 ± 0.02 MΩ. Cell positioning and sealing parameters were set as follows: positioning pressure −60 mbar, minimum seal resistance 0.1 GΩ, holding potential −100 mV, holding pressure −20 mbar. Whole-cell currents were filtered at 5 kHz and acquired at 25 kHz.

HEK-293 cells expressing hNaV1.1–1.7 or tetracycline inducible CHO cells expressing hNaV1.8 (as NaV1.8-HEK cells are unsuitable for patch clamping) were harvested at 70–80% confluence, by washing with Ca2+ and Mg2+ free Dulbecco’s phosphate-buffered saline and incubating with Detachin (Bio-Scientific, NSW, Australia) at 37 °C for 2–5 min. Dissociated cells were then resuspended in Ex-Cell ACF CHO Medium with 25 mM HEPES (Sigma-Aldrich, NSW, Australia) and transferred to the QStirrer (Sophion) and allowed to recover for 30 min. The extracellular solution contained in mM: NaCl 145, KCl 4, CaCl2 2, MgCl2 1, HEPES 10 and glucose 10. The pH was adjusted to 7.4 with NaOH and osmolarity was adjusted with sucrose to 305 mOsm. The intracellular solution contained in mM: CsF 140, EGTA/CsOH 1/5, HEPES 10 and NaCl 10. The pH was adjusted to 7.3 with CsOH and osmolarity adjusted with sucrose to 320 mOsm. P-CTX-1 was diluted in extracellular solution with 0.1% BSA to a concentration of 10 nM and incubated for 5 min. All P-CTX-1 effects were compared to pre-toxin control parameters within the same cell.

Current (I)–voltage (V) relationships were obtained with a holding potential of −80 mV followed by a pre-pulse of −100 mV for 50 ms and a series of 50 ms step pulses that ranged from −80 to + 60 mV in 5 mV increments before returning to a holding potential of −80 mV (repetition interval 5 s). Conductance-voltage relationships were obtained by calculating the conductance (G) at each voltage (V) using the equation G = I/(V − Vrev), where Vrev is the reversal potential. Conductance-voltage curves were fitted with a Boltzmann equation: GNa = GNa,max/1 + exp [(Vm − V1/2)/k], where GNa is the voltage-dependent sodium conductance, GNa,max is the maximal sodium conductance, V1/2 is the potential at which activation is half-maximal, Vm is the membrane potential, and k is the slope factor.

Voltage dependence of steady-state fast inactivation was measured using a series of 500 ms pre-pulses, ranging from −120 to −10 mV in 10 mV increments, followed by a 20 ms pulse of −20 mV for NaV1.1–1.7 and +10 mV for NaV1.8 to assess the available non-inactivated channels (repetition interval 30 s). Peak inward currents (I) were normalised to the maximal inward current (Imax) and fitted using a Boltzmann equation: I/Imax = 1/(1 + exp [(Vm − V1/2)/k)], where Imax is the maximal inward current, V1/2 is the half-maximal sodium current, Vm is the pre-conditioning pulse potential, and k is the slope factor.

Time to peak, fast inactivation time constants and persistent current were determined by a single-pulse protocol, using a holding potential of −80 mV, followed by a pre-pulse of −100 mV for 50 ms and then a 50 ms pulse of −20 mV for NaV1.1–1.7 and +10 mV for NaV1.8. Time to peak was measured from pulse onset to maximal current, fast inactivation time constants were calculated by fitting current decay traces with a single exponential function, and persistent current was determined as the mean current between 40 and 50 ms after pulse onset.

Electrophysiology (NaV1.9)

For hNaV1.9, whole-cell patch-clamp experiments were performed by Icagen Inc (Durham, NC, USA) on a PatchXpress automated electrophysiology platform (Molecular Devices, Sunnyvale, CA, USA) using HEK-293 cells stably expressing hNaV1.9. The extracellular solution for these studies contained in mM: NaCl 135, KCl 5.4, CaCl2 2, MgCl2 1, HEPES 10 and glucose 5. The pH was adjusted to 7.4 with NaOH with a measured osmolarity of 300 mOsm. The intracellular solution contained in mM: CsF 135, EGTA 5, CsCl 10, HEPES 10 and NaCl 5. The pH was adjusted to 7.4 with CsOH with a measured osmolarity of 298 mOsm. P-CTX-1 (1 nM) was diluted in extracellular solution with 0.1% BSA to a concentration of 1 nM and incubated for 5 min. All P-CTX-1 effects were compared to pre-toxin control parameters within the same cell. Current (I)–voltage (V) curves were obtained with a holding potential of −140 mV, then a series of 100 ms step pulses that ranged from −140 to 0 mV in 10 mV increments, followed by a 20 ms pulse of −40 mV to assess the available non-inactivated channels (repetition interval 10 s). Conductance-voltage curves and voltage dependence of steady-state fast inactivation curves were then calculated and fitted as described above.

Single Channel Recordings

Single channel recordings were done in the excised, outside-out patch configuration at room temperature (22 ± 1 °C). Currents were elicited by stepping the clamped voltage from −100 mV to −20 mV before and after exposing the recorded path to 1 nM P-CTX-1 for 10–12 min. The intracellular solution was composed of (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, and 5 EGTA, adjusted to pH 7.4 with CsOH. The control extracellular solution was composed of (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-glucose, adjusted to pH 7.4 with NaOH. Bovine serum albumin at 0.01% was added to all working extracellular solutions.

Recording electrodes were fire polished and had resistances of 5–9 MΩ when filled with intracellular solution. Single channel currents were recorded using an Axon 200B amplifier (Molecular Devices), filtered (−3 dB, 4-pole Bessel) at 5 kHz and sampled at 20 kHz. Currents were filtered offline to 2 kHz for making figures. The single channel active period durations were estimated using QuB software, from idealising events longer that 70 μs (dead time). Single channels activations were defined by a critical shut duration (tcrit) of 5–10 ms (large amplitude) and 20–70 ms (small amplitude). tcrit was calculated for each patch by equalising the area under the longest two shut components in the shut dwell histograms. Data are presented as mean ± SEM from 3–5 patches in all recording conditions.

Retrograde tracing of colonic DRG neurons

Cholera toxin subunit B conjugated to AlexaFluor 488 (CTB-488; Invitrogen, Carlsbad, CA) was injected at three sub-serosal sites within the wall of the distal colon of C57BL/6 mice. After 4 days, animals were humanely killed by CO2 inhalation for subsequent DRG removal and culture56,57.

Dorsal root ganglion isolation and culture

Dorsal root ganglion neurons were isolated and cultured as previously described9,25,48,58. For Na+ imaging experiments, DRGs from T1-L6 were isolated from adult male C57/BL6 mice, male NaV1.8−/− mice or male NaV1.9−/− mice euthanised by CO2 inhalation and collected in DMEM supplemented with 50 μg/ml gentamicin (Sigma), 100 U/ml penicillin, 100 ug/ml streptomycin and 0.25 μg/ml amphotericin B (Life Technologies). DRGs were then incubated for 30 min at 37 °C and 5% CO2 in dissociation media containing 1 mg/ml collagenase (Sigma) and 0.1 mg/ml protease (Sigma). After three wash steps, cells were triturated through a flame-polished glass Pasteur pipette and cultured for 24 h in TNB 100 solution supplemented by TNB 100 lipid-protein-complex, 1 nM NGF, 100 μg/ml streptomycin and penicillin (all from Biochrom, Berlin, Germany) and 200 μg/ml glutamine (Life Technologies) or Neurobasal medium supplemented with B27, 1 nM NGF and 100 μM glutamine (all from Life Technologies, Mulgrave, Vic, Australia) for high content imaging.

For Ca2+ imaging experiments, T10-L1 DRGs from retrogradely traced mice were surgically removed and were digested with 4 mg/mL collagenase II (GIBCO, Life Technologies) plus 4 mg/mL dispase (GIBCO) for 30 min at 37 °C, followed by 4 mg/mL collagenase II for 10 min at 37 °C. Neurons were then mechanically dissociated into a single-cell suspension via trituration through fire-polished Pasteur pipettes. Neurons were resuspended in DMEM (GIBCO) containing 10% FCS (Invitrogen), 2 mM L-glutamine (GIBCO), 100 μM MEM non-essential amino acids (GIBCO), 100 mg/ml penicillin/streptomycin (Invitrogen) and 100 ng/ml NGF (Sigma). Neurons were spot-plated on coverslips coated with poly-D-lysine (800 μg/ml) and laminin (20 μg/ml) and maintained at 37 °C in 5% CO2. Comparisons were made between retrogradely labeled colonic DRG neurons and non-labelled DRG neurons.

Na+ and Ca2+ imaging of cultured DRG neurons

To assess the effect of P-CTX-1 (1 nM) on Na+ and Ca2+ influx in cultured DRG neurons, cells were plated on PDL-coated glass coverslips and after 24 hours in culture incubated with 10 μM Sodium Green-AM (Na+ indicator) or 2.5 μM Fura2-AM (Ca2+ indicator) respectively. Sodium Green -AM was incubated for 1 h at 37 °C while Fura2-AM was incubated for 30 min at room temperature in extracellular fluid (ECS, composition: NaCl 145 mM, KCl 5 mM, CaCl2 1.25 mM, MgCl2 1 mM, glucose 10 mM, HEPES 10 mM) containing 0.02% (v/v) pluronic acid in DMSO. After a brief wash, coverslips were transferrerd to the recording chamber and Na+ or Ca2+ responses were measured at room temperature (~22 °C). Sodium Green was excited at 507 nm with a Polychrome V monochromator (Till Photonics). Images were exposed for 200 μs and acquired at a rate of 1 Hz with a peltier-cooled slow-scan CCD camera system (Imago Sensicam QE, Till Photonics). Data were recorded and further analysed using TILLvisION 4.0.1.3 software (Till Photonics). After a baseline read with extracellular solution or TTX (300 nM), DRG neurons were stimulated with 1 nM P-CTX-1, followed by a final stimulation with 30 mM KCl to identify viable neurons. Na+ responses were analysed as the total fluorescence with responses >1000 fluorescence units defined as responders.

Fura-2 was excited at 340 and 380 nm using a Nikon TE300 Eclipse microscope equipped with a Sutter DG-4/OF wavelength switcher, Omega XF04 filter set for Fura-2, Photonic Science ISIS-3 intensified CCD camera, and Universal Interface Card MetaFluor software. Fluorescence images were obtained every 20 s using a 20x objective. Data were recorded and further analysed using Xcellence software (Olympus) after a baseline fluorescence read with extracellular solution or in the presence of TTX (500 nM). Colonic DRG neurons (identified by the presence of the 488 tracer) were stimulated with 1 nM P-CTX-1, followed by a final stimulation with 40 mM KCl to identify viable neurons. Ca2+ responses were presented as the fluorescence ratio 340/380. Ca2+ maximum peak responses elicited by P-CTX-1 were calculated by subtracting maximum Fura-2 fluorescence (340/380) values to the Fura-2 fluorescence (340/380) values before P-CTX-1 addition.

Single fibre recordings using the murine skin-saphenous nerve preparation

To characterise the pharmacology of P-CTX-1-induced effects on C- and A-fibre afferents, we used extracellular recordings from the murine skin-saphenous nerve preparation as previously described59. The hairy skin of the dorsal hind paw and lower leg of male adult C57BL/6 mice was carefully dissected together with the saphenous nerve, placed in an organ bath chamber with the epithelial side secured in a downward position using white soft paraffin and continuously perfused with carbogenated SIF (composition (mM): NaCl (107.8), KCl (3.5), MgSO4 (0.69), NaHCO3 (26.2), NaH2PO4 (1.67), Na-gluconate (9.64), glucose (5.55), sucrose (7.6) and CaCl2 (1.53); pH 7.3). The desheathed saphenous nerve was placed on a mirror in an adjacent paraffin oil-filled recording chamber and teased into filaments until recordings from single, mechanically excitable receptive fields was achieved. Fibres were classified according to conduction velocity (C-fibre < 1 m/s, A-fibre 1.6–12 m/s) after electrical stimulation of the receptive field with a bipolar teflon coated steel microelectrode (impedance ~ 1 MΩ). The dermal receptive field was then isolated using a plastic ring, and after a 5 min recording period to determine baseline activity, P-CTX-1 (0.5 nM) was perfused at a rate of 5 mL/min at 32 °C for up to 30 min. Fibres without an increase in spontaneous action potential discharge rate after 30 min were considered non-responders. For responding fibres, once spontaneous action potential firing was stable for at least 5 min, NaV subtype-selective inhibitors were sequentially added every 15 min to the perfusate to achieve final concentrations of the NaV1.7 inhibitor Pn3a (1 μM), the NaV1.6 inhibitor GIIIA (10 μM), TTX (1 μM) and the NaV1.8 inhibitor A803467 (10 μM). Data was recorded and analysed using DAPSYS (version 8).

Single fibre colonic afferent recordings using the murine colon-splanchnic nerve preparation

C57BL/6 male mice were humanely killed by CO2 inhalation. The colon and rectum with attached mesentery and splanchnic nerves were removed and afferent recordings performed as described previously24,25,60. Briefly, the colon was removed and pinned flat, mucosal side up, in a specialised organ bath. The colonic compartment was superfused with a modified Krebs solution (in mM: 117.9 NaCl, 4.7 KCl, 25 NaHCO3, 1.3 NaH2PO4, 1.2 MgSO4, 2.5 CaCl2, 11.1 D-glucose), bubbled with carbogen (95% O2, 5% CO2) at a temperature of 34 °C. All preparations contained the L-type calcium channel antagonist nifedipine (1 μM) to suppress smooth muscle activity and the prostaglandin synthesis inhibitor indomethacin (3 μM) to suppress potential inhibitory actions of endogenous prostaglandins. The nerve bundle was extended into a paraffin-filled recording compartment in which finely dissected strands were laid onto a mirror, and single fibre placed on the platinum recording electrode. Action potentials generated by mechanical or chemical stimuli to the colon’s receptive field, pass through the fibres into a differential amplifier, filtered, sampled (20 kHz) using a 1401 interface (Cambridge Electronic Design, Cambridge, UK) and stored on a PC for off-line analysis. P-CTX-1 (1 nM) was added for 5 min via a small metal ring placed over the receptive field of interest in selective experiments the NaV1.8 channel inhibitor A803467 (10 μM) was pre-incubated for 10 min prior co-incubation with P-CTX-1. This route of administration has been previously shown to reproducibly activate afferents25,48,61. Action potentials were analysed off-line using the Spike 2 wavemark function and discriminated as single units on the basis of distinguishable waveform, amplitude and duration.

Colonic afferent classification

Receptive fields were identified by systematically stroking the mucosal surface with a still brush to activate all subtypes of mechanoreceptors. Categorisation of afferents properties was in accordance with our previously published classification system59,62. Briefly, splanchnic nociceptors have high-mechanical activation thresholds, responding to noxious distension (40 mm Hg), stretch (≥7 g) or von Frey hair filaments (2 g) but do not respond to fine mucosal stroking (10 mg von Frey hairs; vfh).

Animal model of P-CTX-1-evoked nocifensive behaviours

To assess the pharmacology of P-CTX-1-evoked nocifensive behaviours, a single dose of P-CTX-1 diluted in sterile saline was administered by subcutaneous injection to the hind paw (intraplantar, i.pl., 40 μl, 10 nM) under brief isoflurane (3%) anaesthesia. To assess the effect of Pn3a on NaV1.7-mediated responses, a single dose of the selective NaV1.7 activator OD1 (40 μl, 300 nM) was administered by i.pl. injection under brief isoflurane (3%) anaesthesia together with increasing concentrations of Pn3a (Suppl. Fig. 1). Nocifensive behaviours including paw lifting, licking and flinching were rated by a blinded observer over a 5 min period. To assess the effects of pharmacological modulators on the development of P-CTX-1 induced pain, compounds were either administered as a second intraplantar injection (TTX, 2 μM) or co-administered with P-CTX-1 by i.pl. injection as appropriately concentrated solutions (TTX, 1 μM; A803467, 10 μM; Pn3a 1 μM; GIIIA, 10 μM). To assess cold allodynia in ciguatoxin-treated animals, mice were placed on a temperature-controlled Peltier plate (Ugo Basile, Comerio, Italy) once spontaneous pain behaviours subsided to <10 counts/5 min and the number of paw shakes, lifts, licks or flinches was quantified over a 5 min period at 15 °C. Injection of equal volumes of sterile saline did not elicit any nocifensive behaviour.

Animal model of P-CTX-1-evoked visceral pain

To assess the contribution of NaV isoforms to the gastrointestinal symptoms associated with ciguatera, we established a novel model of P-CTX-1-induced visceral hypersensitivity. Male C57BL/6 mice house on AlphaDri bedding were fasted overnight with ad-libitum access to water. P-CTX-1 (10 nM, 50 μl) in sterile saline was administered under light isoflurane (3%) anaesthesia via a soft, flexible, round-tipped catheter that was advanced 3 cm from the anus. The NaV1.8 blocker A-803467 (100 mg/kg) was diluted in PEG400 and administered in a volume of 2 μl/g by intraperitoneal injection as previously described62. To avoid systemic adverse effects TTX (100 nM) was co-administered by intra-colonic administration with P-CTX-1. Animals were allowed to recover for 15 min and then placed into the recording chamber of a Behavioral Spectrometer (Behavioral Instruments, Hillsborough, NJ, USA) for automatic detection of still, grooming, orienting, rearing and locomotion behaviours as previously described by combining video and vibration analysis64.

Phosphorylated MAP kinase ERK 1/2 (pERK) quantification in spinal cord

Mice were anaesthetised in an isofluorane chamber and received an enema of either vehicle (0.3% bovine serum albumin in 0.1 M phosphate buffer saline) or P-CTX-1 (1 nM in 0.3% bovine serum albumin in 0.1 M phosphate buffer saline). After 5 minutes mice were injected with an anaesthetic overdose (0.125 ml/250 g sodium pentobarbitone) and within 4 min underwent transcardial perfuse fixation with warm saline (0.85% physiological sterile saline) followed by ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer (Sigma-Aldrich, MO, USA). Following transcardial perfusion thoracolumbar (T10-L1) spinal cord was removed, using the lowest rib as an anatomical marker of T13, and post-fixed for 16 hours at 4 °C in 4% paraformaldehyde in 0.1 M phosphate buffer. Following fixation spinal cord were cryoprotected in 30% sucrose/phosphate buffer (Sigma-Aldrich, MO, USA) overnight at 4 °C and then placed in 50% Optimal Cutting Temperature compound (OCT; Tissue-Tek, Sakura Finetek, CA, USA) in 30% sucrose/phosphate buffer solution for 7 h, before block freezing in 100% OCT. Frozen sections (15 μm) were cut using a cryostat and placed onto saline coated slides for fluorescent immunohistochemistry.

Immunohistochemistry for pERK was performed in a paired fashion, with tissue from saline or P-CTX-1 treated mice run simultaneously. Following 20 min of air drying, sections were flushed 3 times with PBS and incubated with 5% normal chicken serum/0.2% Triton-X 200 (Sigma-Aldrich, MO, USA) in PBS (0.2% TX-PBS) for 30 min at room temperature to block non-specific binding of secondary antibodies. Sections were then incubated for 18 h at room temperature with monoclonal anti-sera rabbit anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (pERK; 1:200; Cell Signalling Technology #4370) diluted in 0.2% TX-PBS. Sections were then washed 3 times with 0.2% TX-PBS before being incubated for 1 h at room temperature with secondary antibody chicken anti-rabbit AlexaFluorR488 (AF-488). Negative controls were prepared as above with the primary antibody omitted.

NaV isoform expression studies using Quantitative-Reverse-Transcription-Polymerase-Chain-Reaction (QRT-PCR)

Whole DRG QRT-PCR

RNA was extracted isolated using the PureLink RNA Micro kit (Invitrogen, cat #12183-016) and DNAse treated (LifeTechnologies cat #12185-010) following the manufacturer’s instruction. RNA was stored at −80 °C in aliquots of 1–3 μl. QRT-PCR was performed using EXPRESS One-Step Superscript® qRT-PCR Kit (Life Technologies cat #11781-01 K) with commercially available hydrolysis probes (TaqMan®; LifeTechnologies, see Table 3 for details) and DEPC-treated water (AMBION cat #AM9916). For each reaction, 10 μl qPCR SuperMix, 1 μl TaqMan® primer assay, 0.04 μl ROX, 2 μl water, 2 μl SuperScript Reverse Transcriptase and 5 μl RNA (45 ng/well, except human colon biopsies at 30 ng/well) was used in all experiments. Beta-actin was used as reference gene. PCR runs were performed in duplicate for each sample on a 7500 Fast machine (Applied Biosystems).

Table 3: TaqMan® hydrolysis probes used for quantitative PCR.

Single Cell PCR of colonic DRG neurons

AlexaFluor488 conjugated cholera-toxin subunit β retrograde traced single cells were picked using a micromanipulator under an Olympus microscope equipped with appropriate fluorescent filter. Cells were under a continuous flow of sterile and RNA/DNAse free PBS in order to reduce contamination. After a cell was picked, the glass capillary was broken into a tube containing 10 μl of lysis buffer and DNAse (TaqMan® Gene Expression Cells-to-CT™ Kit). For every coverslip a bath control was analysed together with other samples. Tubb3 expression served as positive control, with GFAP expression measured to exclude contamination with glial cells.

Statistical analysis

Data are represented as mean ± SEM. Statistical significance was defined as p < 0.05 and was determined using paired or unpaired student’s t-tests and One-way ANOVA analysis with post-tests as indicated. Statistical analysis was performed using GraphPad Prism Version 6.00.

Additional Information

How to cite this article: Inserra, M. C. et al. Multiple sodium channel isoforms mediate the pathological effects of Pacific ciguatoxin-1. Sci. Rep. 7, 42810; doi: 10.1038/srep42810 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    , & In Seafood and freshwater toxins: pharmacology, physiology, and detection (ed ) 925–950 (CRC Press, 2014).

  2. 2.

    et al. Ciguatera Fish Poisoning in the Pacific Islands (1998 to 2008). Plos Neglected Tropical Diseases 5, doi: 10.1371/journal.pntd.0001416 (2011).

  3. 3.

    et al. Production of ciguatoxin and maitotoxin by strains of Gambierdiscus australes, G. pacificus and G. polynesiensis (Dinophyceae) isolated from Rarotonga, Cook Islands. Harmful Algae 39, 185–190, doi: (2014).

  4. 4.

    et al. Ciguatera fish poisoning and sea surface temperatures in the Caribbean Sea and the West Indies. Toxicon 56, 698–710, doi: 10.1016/j.toxicon.2010.02.026 (2010).

  5. 5.

    Epidemiology and Clinical Features of Ciguatera Fish Poisoning in Hong Kong. Toxins 6, 2989–2997, doi: 10.3390/toxins6102989 (2014).

  6. 6.

    Emergence and Epidemiology of Ciguatera in the Coastal Cities of Southern China. Marine Drugs 13, 1175–1184, doi: 10.3390/md13031175 (2015).

  7. 7.

    et al. Ciguatera and Scombroid Fish Poisoning in the United States. Foodborne Pathogens and Disease 10, 1059–1066, doi: 10.1089/fpd.2013.1514 (2013).

  8. 8.

    et al. Ciguatera fish poisoning: a first epidemic in Germany highlights an increasing risk for European countries. Toxicon 91, 76–83, doi: 10.1016/j.toxicon.2014.10.016 (2014).

  9. 9.

    et al. Ciguatoxins activate specific cold pain pathways to elicit burning pain from cooling. EMBO J 31, 3795–3808, doi: 10.1038/emboj.2012.207 (2012).

  10. 10.

    & Ciguatera: recent advances but the risk remains. International journal of food microbiology 61, 91–125, doi: 10.1016/s0168-1605(00)00382-2 (2000).

  11. 11.

    & Ciguatoxins: Cyclic polyether modulators of voltage-gated Iion channel function. Marine Drugs 4, 82–118 (2006).

  12. 12.

    Clinical aspects of ciguatera (fish poisoning) in French Polynesia. Hawaii medical journal 28, 25–28 (1968).

  13. 13.

    , & Clinical observations on 3,009 cases of ciguatera (fish poisoning) in the South Pacific. The American journal of tropical medicine and hygiene 28, 1067–1073 (1979).

  14. 14.

    Ciguatera fish poisoning. Annual review of medicine 33, 97–111, doi: 10.1146/annurev.me.33.020182.000525 (1982).

  15. 15.

    , & Treatment of ciguatera fish poisoning with amitriptyline and nifedipine. Journal of toxicology. Clinical toxicology 25, 423–428 (1987).

  16. 16.

    , & Brevetoxins, unique activators of voltage-sensitive sodium channels, bind to specific sites in rat brain synaptosomes. Molecular pharmacology 30, 129–135 (1986).

  17. 17.

    Marine toxins targeting ion channels. Marine Drugs 4, 37–69, doi: 10.3390/md403037 (2006).

  18. 18.

    , & Electrophysiological studies on ciguatera poisoning in man (Part II). Journal of the neurological sciences 101, 93–97 (1991).

  19. 19.

    The changing face of ciguatera. Toxicon 39, 97–106 (2001).

  20. 20.

    , & Differential actions of pacific ciguatoxin-1 on sodium channel subtypes in mammalian sensory neurons. The Journal of pharmacology and experimental therapeutics 288, 379–388 (1999).

  21. 21.

    , & Ciguatoxin (CTX-1) modulates single tetrodotoxin-sensitive sodium channels in rat parasympathetic neurones. Neuroscience Letters 252, 103–106, doi: 10.1016/s0304-3940(98)00575-8 (1998).

  22. 22.

    & Characterization of endogenous calcium responses in neuronal cell lines. Biochem Pharmacol 79, 908–920 (2010).

  23. 23.

    et al. Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a. Scientific Reports (Accepted for publication 12/12/2016).

  24. 24.

    et al. Selective role for TRPV4 ion channels in visceral sensory pathways. Gastroenterology 134, 2059–2069, doi: 10.1053/j.gastro.2008.01.074 (2008).

  25. 25.

    et al. The ion channel TRPA1 is required for normal mechanosensation and is modulated by algesic stimuli. Gastroenterology 137, 2084–2095 e2083, doi: 10.1053/j.gastro.2009.07.048 (2009).

  26. 26.

    & Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat Rev Gastroenterol Hepatol 11, 611–627, doi: 10.1038/nrgastro.2014.103 (2014).

  27. 27.

    et al. Analgesic treatment of ciguatoxin-induced cold allodynia. Pain 154, 1999–2006, doi: 10.1016/j.pain.2013.06.015 (2013).

  28. 28.

    et al. Purification and characterization of ciguatoxins from moray eel (Lycodontis javanicus, Muraenidae). Toxicon 29, 1115–1127 (1991).

  29. 29.

    et al. The use of the mosquito bioassay for determining the toxicity to man of ciguateric fish. Biological Bulletin 172, 137–143, doi: 10.2307/1541614 (1987).

  30. 30.

    & Bioavailability and intravenous toxicokinetic parameters for Pacific ciguatoxin P-CTX-1 in rats. Toxicon 64, 81–86, doi: 10.1016/j.toxicon.2012.12.026 (2013).

  31. 31.

    , & Toxicokinetics of the ciguatoxin P-CTX-1 in rats after intraperitoneal or oral administration. Toxicology 284, 1–6, doi: 10.1016/j.tox.2011.02.005 (2011).

  32. 32.

    , , & A novel N440K sodium channel mutation causes myotonia with exercise-induced weakness–exclusion of CLCN1 exon deletion/duplication by MLPA. Acta Myol 30, 133–137 (2011).

  33. 33.

    et al. Sodium channel alpha-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): Different expression patterns in developing rat nervous system. Mol Brain Res 45, 71–82, doi: 10.1016/S0169-328x(96)00241-0 (1997).

  34. 34.

    et al. Synthetic ciguatoxins selectively activate Nav1.8-derived chimeric sodium channels expressed in HEK293 cells. The Journal of biological chemistry 284, 7597–7605, doi: 10.1074/jbc.M806481200 (2009).

  35. 35.

    , & Identification of peptide components of the brevetoxin receptor site of rat brain sodium channels. The Journal of biological chemistry 269, 19904–19909 (1994).

  36. 36.

    et al. Allosteric modulation of neurotoxin binding to voltage-sensitive sodium channels by Ptychodiscus brevis toxin 2. Molecular pharmacology 31, 273–278 (1987).

  37. 37.

    et al. Spinal sensory neurons express multiple sodium channel alpha-subunit mRNAs. Brain Res Mol Brain Res. 43(1-2), 117–31 (31 Dec 1996).

  38. 38.

    et al. Sodium-calcium exchanger and multiple sodium channel isoforms in intra-epidermal nerve terminals. Mol Pain 6, 84, doi: 10.1186/1744-8069-6-84 (2010).

  39. 39.

    , & Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol 86, 629–640 (2001).

  40. 40.

    , , & Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 22, 8352–8356 (2002).

  41. 41.

    , & Role of TTX-sensitive and TTX-resistant sodium channels in Adelta- and C-fiber conduction and synaptic transmission. J Neurophysiol 99, 617–628, doi: 10.1152/jn.00944.2007 (2008).

  42. 42.

    et al. An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. Pain 154, 1749–1757, doi: 10.1016/j.pain.2013.05.032 (2013).

  43. 43.

    , & Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. The Journal of neuroscience: the official journal of the Society for Neuroscience 18, 9607–9619 (1998).

  44. 44.

    et al. Sensory and electrophysiological properties of guinea-pig sensory neurones expressing Nav 1.7 (PN1) Na+ channel alpha subunit protein. The Journal of physiology 546, 565–576 (2003).

  45. 45.

    , & Sodium channel Na(v)1.6 is expressed along nonmyelinated axons and it contributes to conduction. Brain Res Mol Brain Res 105, 19–28 (2002).

  46. 46.

    et al. Sodium channel Na(v)1.6 is localized at nodes of ranvier, dendrites, and synapses. Proc Natl Acad Sci USA 97, 5616–5620, doi: 10.1073/pnas.090034797 (2000).

  47. 47.

    et al. Fibroblast growth factor homologous factor 2B: association with Nav1.6 and selective colocalization at nodes of Ranvier of dorsal root axons. The Journal of neuroscience: the official journal of the Society for Neuroscience 24, 6765–6775, doi: 10.1523/JNEUROSCI.1628-04.2004 (2004).

  48. 48.

    et al. Selective spider toxins reveal a role for the Nav1.1 channel in mechanical pain. Nature 534, 494–499, doi: 10.1038/nature17976 (2016).

  49. 49.

    , & The mouse ciguatoxin bioassay: a dose-response curve and symptomatology analysis. Toxicon 21, 363–369 (1983).

  50. 50.

    et al. Repeat exposure to ciguatoxin leads to enhanced and sustained thermoregulatory, pain threshold and motor activity responses in mice: relationship to blood ciguatoxin concentrations. Toxicology 246, 55–62, doi: 10.1016/j.tox.2007.12.013 (2008).

  51. 51.

    , , & Block of voltage-gated potassium channels by Pacific ciguatoxin-1 contributes to increased neuronal excitability in rat sensory neurons. Toxicology and applied pharmacology 204, 175–186, doi: 10.1016/j.taap.2004.08.020 (2005).

  52. 52.

    et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 2, 541–548, doi: 10.1038/9195 (1999).

  53. 53.

    , , & GTP up-regulated persistent Na+ current and enhanced nociceptor excitability require NaV1.9. J Physiol 586, 1077–1087, doi: 10.1113/jphysiol.2007.147942 (2008).

  54. 54.

    et al. Biophysical and Pharmacological Characterization of Nav1.9 Voltage Dependent Sodium Channels Stably Expressed in HEK-293 Cells. PloS one 11, e0161450, doi: 10.1371/journal.pone.0161450 (2016).

  55. 55.

    et al. Development of a muO-Conotoxin Analogue with Improved Lipid Membrane Interactions and Potency for the Analgesic Sodium Channel NaV1.8. The Journal of biological chemistry 291, 11829–11842, doi: 10.1074/jbc.M116.721662 (2016).

  56. 56.

    et al. alpha-Conotoxin Vc1.1 inhibits human dorsal root ganglion neuroexcitability and mouse colonic nociception via GABAB receptors. Gut, doi: 10.1136/gutjnl-2015-310971 (2016).

  57. 57.

    et al. Sprouting of colonic afferent central terminals and increased spinal mitogen-activated protein kinase expression in a mouse model of chronic visceral hypersensitivity. J Comp Neurol 520, 2241–2255, doi: 10.1002/cne.23042 (2012).

  58. 58.

    et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature 447, 855–858, doi: 10.1038/nature05880 (2007).

  59. 59.

    et al. Phenotyping sensory nerve endings in vitro in the mouse. Nat Protoc 4, 174–196, doi: 10.1038/nprot.2008.223 (2009).

  60. 60.

    , , & Splanchnic and pelvic mechanosensory afferents signal different qualities of colonic stimuli in mice. Gastroenterology 127, 166–178 (2004).

  61. 61.

    et al. Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients. Brain Behav Immun 42, 191–203, doi: 10.1016/j.bbi.2014.07.001 (2014).

  62. 62.

    , & Post-inflammatory modification of colonic afferent mechanosensitivity. Clin Exp Pharmacol Physiol 36, 1034–1040, doi: 10.1111/j.1440-1681.2009.05248.x (2009).

  63. 63.

    et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA 104, 8520–8525, doi: 10.1073/pnas.0611364104 (2007).

  64. 64.

    et al. Validation and implementation of a novel high-throughput behavioral phenotyping instrument for mice. J Neurosci Methods 224, 48–57, doi: 10.1016/j.jneumeth.2013.12.010 (2014).

Download references

Acknowledgements

I.V. is an Australian Research Council Future Fellow. This study was supported by the Australian National Health and Medical Research Council (NHMRC) project grant APP1045592 (I.V., K.Z.) and APP1083480 (S.M.B.). S.M.B. is an NHMRC R.D Wright Biomedical Research Fellow, A.M.H. received funding from an ARC Discovery Early Career Research Award (DECRA), and R.J.L. is an NHMRC Principal Research Fellow.

Author information

Author notes

    • Marco C. Inserra
    • , Mathilde R. Israel
    • , Ashlee Caldwell
    • , Joel Castro
    •  & Jennifer R. Deuis

    These authors contributed equally to this work.

Affiliations

  1. Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, 306 Carmody Rd, St Lucia, Queensland 4072, Australia

    • Marco C. Inserra
    • , Mathilde R. Israel
    • , Jennifer R. Deuis
    • , Richard J. Lewis
    •  & Irina Vetter
  2. Visceral Pain Group, South Australian Health and Medical Research Institute (SAHMRI), School of Medicine, Flinders University, Adelaide, South Australia 5000, Australia

    • Ashlee Caldwell
    • , Joel Castro
    • , Andrea M. Harrington
    • , Sonia Garcia-Caraballo
    • , Jessica Maddern
    • , Andelain Erickson
    • , Luke Grundy
    •  & Stuart M. Brierley
  3. Centre for Nutrition and Gastrointestinal Diseases, Discipline of Medicine, University of Adelaide, South Australian Health and Medical Research Institute (SAHMRI), North Terrace, Adelaide, South Australia 5000, Australia

    • Ashlee Caldwell
    • , Joel Castro
    • , Andrea M. Harrington
    • , Sonia Garcia-Caraballo
    • , Jessica Maddern
    • , Andelain Erickson
    • , Luke Grundy
    • , Grigori Y. Rychkov
    •  & Stuart M. Brierley
  4. Queensland Brain Institute, The University of Queensland, St Lucia, Queensland 4072, Australia

    • Angelo Keramidas
  5. Klinik für Anästhesiologie am Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany

    • Katharina Zimmermann
  6. School of Pharmacy, The University of Queensland, 20 Cornwall St, Woolloongabba, Queensland 4102, Australia

    • Irina Vetter

Authors

  1. Search for Marco C. Inserra in:

  2. Search for Mathilde R. Israel in:

  3. Search for Ashlee Caldwell in:

  4. Search for Joel Castro in:

  5. Search for Jennifer R. Deuis in:

  6. Search for Andrea M. Harrington in:

  7. Search for Angelo Keramidas in:

  8. Search for Sonia Garcia-Caraballo in:

  9. Search for Jessica Maddern in:

  10. Search for Andelain Erickson in:

  11. Search for Luke Grundy in:

  12. Search for Grigori Y. Rychkov in:

  13. Search for Katharina Zimmermann in:

  14. Search for Richard J. Lewis in:

  15. Search for Stuart M. Brierley in:

  16. Search for Irina Vetter in:

Contributions

M.R.I., J.R.D. and I.V. performed high-throughput membrane potential assays; M.C.I. and J.R.D. performed whole-cell patch clamp experiments; A.K. performed single channel experiments; M.R.I. performed skin afferent recordings; J.R.D., M.R.I. and I.V. performed in vivo experiments; M.C.I. performed Na+ imaging experiments; A.C., J.C., A.M.H., S.G.C., J.M., A.E., L.G. performed colonic afferent recordings, pERK immunohistochemistry, NaV isoform expression analysis and Ca2+ imaging experiments; G.Y.R., K.Z., R.J.L., I.V. and S.M.B. contributed to experimental design; I.V. and S.M.B. interpreted data and wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Stuart M. Brierley or Irina Vetter.

Supplementary information

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Creative Commons BYThis work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/